Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure - Graf, Christiana; D’Ambrosio, Roberta; Degasperi, Elisabetta; Paolucci, Stefania; Llaneras, Jordi; Vermehren, Johannes; Dultz, Georg; Peiffer, Kai-Henrik; Finkelmeier, Fabian; Herrmann, Eva; Zeuzem, Stefan; Buti, Maria; et al. (JHEP reports, 2024)
Keywords: DAA treatment failure; Gastroenterology and Hepatology; Hepatitis C virus; Re-treatment; Voxilaprevir/velpatasvir/sofosbuvir; PP; DAA; Voxilaprevir/velpatasvir/sofosbuvir; DAA treatment failure; G/P; RASs; EOT; SOF; GT; SVR; IFN; Hepatitis C virus; VEL; Re-treatment; CTP; VOX; LDV; per protocol; velpatasvir; Child-Turcotte-Pugh; sustained virological response; voxilaprevir; resistance-associated substitutions; interferon; genotype; ledipasvir; sofosbuvir; direct-acting antiviral; end of treatment; glecaprevir/pibrentasvir